Information Provided By:
Fly News Breaks for March 2, 2020
Mar 2, 2020 | 12:07 EDT
H.C. Wainwright analyst Edward White raised the firm's price target on Karyopharm to $43 from $40 and reiterated a Buy rating on the shares. The price target raise followed positive results from Karyopharm's BOSTON study for Xpovio in Multiple Myeloma, with the trial's primary endpoint of a statistically significant increase in progression free survival reached. White said he now sees an "increased probability of success estimate for Xpovio in combination treatment for multiple myeloma" and he has increased his Xpovio sales estimates.